QX77 |
Katalog-Nr.GC32962
One-Click Copy Product Info
|
QX77 ist ein Chaperon-vermittelter Autophagie (CMA)-Aktivator und reguliert die LAMP2A-Expression in vitro hoch. QX77 induziert die Rab11-Hochregulierung, rettet die Rab11-Herunterregulierung und den Trafficking-Mangel in zystinotischen Zellen. QX77 kann die Selbsterneuerung behindern und die Differenzierung von ES-Zellen fÖrdern.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1798331-92-6
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
QX77 is a chaperone-mediated autophagy (CMA) activator[1]. QX77 can activate CMA to ameliorate intracellular trafficking defects[2], and also reduce ferroptosis and alleviate oxidative stress[3-4].
In vitro, when human pancreatic stellate cells (HPSCs) treated with TGF-β1 were co-treated with QX77 (5ng/mL) and 20ng/mL MFG-E8 for 24 hours, QX77 eliminated the inhibitory effect of MFG-E8 on the TGF-β1-induced upregulation of LAMP2A expression and downregulation of MEF2D expression. QX77 attenuated the mitigating effect of MFG-E8 on oxidative stress[5]. In SKOV3/DDP cells treated with DDP (6μg/mL), intervention with QX77 (10μM) for 12 hours enhanced cell viability and affected the expression and localization of autophagy-related proteins[6].
In vivo, in a diabetic rat model, intravitreal injection of QX77 (2.5mg/kg) was administered once per week starting from the first day of model establishment for a duration of 2 weeks. QX77 significantly improved diabetes-induced impairment of retinal physiological function, reduced the expression of ACSL4 protein, decreased MDA levels and the accumulation of the toxic lipid peroxidation product 4-HNE in the retina, and reduced the number of autophagosomes, demonstrating a protective effect against early diabetic retinopathy[4].
References:
[1] Rahman F, Johnson JL, Ait Kbaich M, et al. Reconstitution of Rab11-FIP4 Expression Rescues Cellular Homeostasis in Cystinosis. Mol Cell Biol. 2024;44(12):577-589.
[2] Li J, Zeng S, Sun Y, et al. Gluconic acid alleviates hypertrophic scar formation through binding PLOD1, reducing p-AKT signaling and activating autophagy. Phytomedicine. 2025 Jul 25;143:156825.
[3] Liu C, Sun W, Zhu T, et al. Glia maturation factor-β induces ferroptosis by impairing chaperone-mediated autophagic degradation of ACSL4 in early diabetic retinopathy. Redox Biol. 2022 Jun;52:102292.
[4] Ren Y, Cui Q, Zhang J, et al. Z Milk Fat Globule-EGF Factor 8 Alleviates Pancreatic Fibrosis by Inhibiting ER Stress-Induced Chaperone-Mediated Autophagy in Mice. Front Pharmacol. 2021 Aug 5;12:707259.
[5] Du P, Xu X, Wang Y. Hsa_circ_0000585 promotes chemoresistance to cis-platin in epithelial cells of ovarian cancer by modulating autophagy. Biochem Biophys Res Commun. 2023 Oct 20;678:186-192.
| Cell experiment [1]: | |
Cell lines | Human pancreatic stellate cells (HPSCs) |
Preparation Method | HPSCs were cultured in Ham's F-12K medium supplemented with 20% fetal bovine serum (FBS) at 37°C, 5% CO₂. HPSCs were treated with TGF-β1 (5ng/mL) to induce activation, with or without QX77 (5ng/mL) and recombinant human MFG-E8 (20ng/mL) for 24 hours. |
Reaction Conditions | 5ng/mL; 24h |
Applications | QX77 upregulated LAMP2A expression and reversed the inhibitory effects of MFG-E8 on TGF-β1-induced CMA in HPSCs. QX77 also eliminated MFG-E8's suppressive effects on collagen I and α-SMA expression, as well as MFG-E8's reduction of oxidative stress in activated HPSCs. |
| Animal experiment [2]: | |
Animal models | Sprague-Dawley (SD) rats |
Preparation Method | Diabetic rats were established by streptozotocin (STZ) injection. QX77 (2.5mg/kg) was intravitreally injected on the first day of detectable hyperglycemia and maintained for 2 weeks. Animals were sacrificed for retinal analysis. |
Dosage form | 2.5mg/kg; i.p. |
Applications | QX77 significantly rescued retinal physiological function by reducing ACSL4 protein expression and lipid peroxidation (MDA and 4-HNE levels) in the RPE-Bruch's membrane-choriocapillaris complex. |
References: | |
| Cas No. | 1798331-92-6 | SDF | |
| Canonical SMILES | CC(NC1=CC=C(C2=NC3=CC=C(Cl)C=C3OC2)C=C1)=O | ||
| Formula | C16H13ClN2O2 | M.Wt | 300.74 |
| Löslichkeit | DMSO : ≥ 64 mg/mL (212.81 mM) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.3251 mL | 16.6257 mL | 33.2513 mL |
| 5 mM | 665 μL | 3.3251 mL | 6.6503 mL |
| 10 mM | 332.5 μL | 1.6626 mL | 3.3251 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 28 reference(s) in Google Scholar.)